Cannabis stocks surged after President Joe Biden announced plans to work on rescheduling marijuana under the Controlled Substances Act. The move could have significant positive implications for the cannabis industry and its investors.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
President Biden’s post on X (let’s call it a tweet for simplicity’s sake) highlighted the bad side effects of the current marijuana policies. By proposing to reclassify cannabis from a Schedule I to a Schedule III drug, the Department of Justice would ultimately reduce the federal burdens on marijuana users and sellers. Frustratingly, the industry can not claim complete victory. The change had to stop short of full legalization because that remains within Congress’ purview.
In his tweet on X, the U.S. President expressed sadness for what he termed “…our failed approach to marijuana.”
Immediate Market Reaction
The announcement sparked a buying spree among investors. Canadian producer Canopy Growth (NYSE:CGC) saw its stock jump 15% to $11.95. Multistate operators like Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), and Trulieve Cannabis (TCNNF) also experienced significant gains. This sudden jump demonstrates the market’s optimism about the potential easing of federal restrictions and the broadening of new opportunities for these companies.
Potential Benefits for the Industry
Rescheduling marijuana to a Schedule III substance could lead to several benefits for the cannabis industry. First, it would allow state-licensed sellers to deduct their operating expenses on federal tax returns, which is not possible under the current Schedule I classification. This change would reduce the effective federal tax rates that these businesses face, potentially leading to increased profitability and reinvestment in the industry.
Second, rescheduling could improve access to banking services. Currently, the illegality of marijuana under federal law prevents cannabis companies from accessing federally regulated banks, pensions, and mutual funds. This forces companies to list their shares in Canada or trade on less liquid over-the-counter (OTC) systems in the U.S. Easier access to banking services would enhance the financial stability and growth prospects of cannabis businesses.
Marijuana Rescheduling Presents Investor Opportunities
The rescheduling news presents new opportunities for investors. Shares of companies like Curaleaf Holdings, Green Thumb Industries, and Trulieve Cannabis are likely to benefit from the regulatory shift. Given their established presence in the 36 states that allow licensed cannabis sales, investing in these multistate operators could be a smart strategic move.
Key Takeaway: A Unique Chance for Investors
President Biden’s proposal to reschedule marijuana as a Schedule III drug has injected new optimism into the cannabis market. The move could reduce federal tax burdens, improve access to banking services, and enhance investment opportunities in the industry. As the regulatory landscape evolves, investors have a unique chance to capitalize on the potential growth of the cannabis sector.
